Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia

• DOI: 10.1160/th14-04-0342
• Publication Date: 2015-01-08T07:46:51Z
• Authors: Hai Zhou; Yu Hou; Xuena Liu; Jihua Qiu; Qi Feng; Yawen Wang; Xu Zhang; Yanan Min; Linlin Shao; Xinguang Liu; Guosheng Li; Lizhen Li; Lei Yang; Shuqian Xu; Heyu Ni; Jun Peng; Ming Hou
• Keywords: Decitabine; Thrombopoiesis

Impaired megakaryocyte maturation and insufficient platelet production have been shown to participate in the pathogenesis of immune thrombocytopenia (ITP). Our previous study demonstrated that low expression tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) megakaryocytes contributed impaired ITP. Decitabine (DAC), a demethylating agent, is known promote cell differentiation at doses. However, whether decitabine potential promoting release ITP unclear. In this study, we evaluated effect DAC on presence plasma has cause production. We observed low-dose (10 nM) could significantly increase number mature polyploid (≥ 4N) cultures with from healthy controls more than one-half patients vitro. Furthermore, platelets released these increased compared those untreated DAC. megakaryocytes, enhanced TRAIL via decreasing its promoter methylation status. These findings demonstrate can enhance The therapeutic role may be beneficial for thrombocytopenic disorders.